Welcome to our dedicated page for Novanta news (Ticker: NOVT), a resource for investors and traders seeking the latest updates and insights on Novanta stock.
Novanta Inc. reports developments as a Nasdaq-listed supplier of core technology solutions for medical, life science and advanced industrial original equipment manufacturers. Its updates center on precision medicine, precision manufacturing, robotics and automation, and advanced surgery, including laser beam steering and scanning, laser sources, robotic and precision motion technologies, medical insufflators, endoscopic pumps and integrated operating room technologies.
Company news commonly covers quarterly earnings releases, conference calls, investor presentations, OEM design wins, product and technology collaborations, and capital actions tied to balance-sheet and securities structure. Recent themes include motion control and sensing technologies for robotics certification environments and tangible equity unit financing.
Novanta reported a strong first quarter 2022, with GAAP revenue rising 26% to $204 million and net income of $18.8 million. Adjusted EPS increased 26% to $0.73, while Adjusted EBITDA grew 33% to $43.6 million. Customer demand remains robust, with a record backlog of $586 million and an organic revenue growth of 7.4%. Novanta expects continued strong growth in Q2 2022, with revenue guidance of $205 million to $213 million despite macroeconomic challenges.
Celera Motion, a unit of Novanta, announced new sizes and capabilities for its Aura Absolute Chip Encoder Series. These encoders cater to high-volume OEM applications such as surgical robots and cobots. The Aura line features built-in eccentricity compensation, high resolution, and low-power consumption. New customizable scale sizes range from 18 mm to 63.5 mm for rotary and 9 mm to 195 mm for linear applications. This expansion aims to enhance precision in motion-control solutions while addressing customer demands for high performance.
Novanta Inc. (NASDAQ: NOVT) will release its first quarter 2022 results on May 10, 2022. A conference call is scheduled for 10:00 a.m. ET the same day, available via dial-in or live webcast on Novanta's investor relations page. The call will provide insights into the company's performance and strategic direction. A replay of the call will be accessible three hours afterward and will remain available until July 4, 2022. Novanta specializes in technology solutions for healthcare and advanced industrial OEMs, focusing on photonics, vision, and precision motion.
Novanta reported strong financial results for the full year 2021, with GAAP revenue of $706.8 million, a 19.7% increase from 2020, and net income of $50.3 million. The diluted EPS rose to $1.41, up from $1.25 in the previous year. In Q4 2021, revenue reached $199 million, marking a 34.9% increase year-over-year. Adjusted EBITDA was $152.7 million for the full year. Despite challenges such as supply chain disruptions, Novanta enters 2022 with a record backlog of $569 million and anticipates revenue between $825 million to $845 million.
Novanta Inc. (NASDAQ: NOVT) will release its fourth quarter and full year 2021 results on March 01, 2022, followed by a conference call at 10:00 a.m. ET. Investors can join the call by dialing (888) 346-3959 or via live webcast on Novanta's website. A replay will be available three hours post-call, accessible until April 04, 2022. Novanta specializes in technology solutions for healthcare and advanced industrial OEMs, focusing on photonics, vision, and precision motion to provide competitive advantages.
Novanta Inc. (NASDAQ: NOVT) announced that Chief Financial Officer Robert Buckley and Executive Vice President Charlie Webster will present at the CJS Securities 22nd Annual New Ideas for the New Year Investor Conference on Wednesday, January 12, 2022. Novanta is a leading global supplier of technology solutions for medical and advanced industrial OEMs, focusing on photonics, vision, and precision motion. The company's innovative team drives its success by addressing complex technical challenges, enhancing performance and precision in applications.
Novanta Inc. (NASDAQ:NOVT) announced that Matthijs Glastra, Chairperson and CEO, along with CFO Robert Buckley, will present at the J.P. Morgan Healthcare Conference on January 11, 2022, in San Francisco, California. As a leading global supplier of core technology solutions, Novanta enables medical and advanced industrial OEMs to achieve a competitive advantage through its expertise in photonics, vision, and precision motion. The company focuses on delivering high-performance components tailored to demanding applications, driven by a commitment to innovation and customer success.
Novanta Inc. reported strong Q3 2021 results, achieving GAAP revenue of $177.7 million, a 24.3% increase from Q3 2020. GAAP net income reached $14 million, with diluted EPS of $0.38. Adjusted diluted EPS rose to $0.75, reflecting robust demand in advanced industrial and medical sectors. Notably, bookings surged 84% year-over-year. The company raised its 2021 revenue guidance to between $693 million and $703 million, expecting fourth quarter revenue of $185 million to $195 million, illustrating strong market momentum despite ongoing supply chain challenges.
Novanta Inc. (Nasdaq: NOVT) announced that CEO Matthijs Glastra and CFO Robert Buckley will present at Baird's 2021 Global Industrial Conference on November 10, 2021. The conference will be held virtually. Novanta is recognized for providing advanced technology solutions to medical and industrial OEMs, enabling them to achieve competitive advantages through precision and performance. Their expertise lies in photonics, vision, and precision motion technologies. For more information, visit www.novanta.com.
Novanta Inc. (Nasdaq: NOVT) is set to release its third quarter 2021 financial results on November 09, 2021. The company will also host a conference call at 10:00 a.m. ET on the same day to discuss these results. Interested parties can join the call by dialing (888) 346-3959 or through a live webcast on the company’s website. A replay will be available three hours post-call until January 03, 2022.
Novanta provides advanced technology solutions aimed at enhancing the competitive edge of healthcare and industrial OEMs.